Rodney L. Piatt

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

The University of Tampa, Inc. functions as a college/university that offers undergraduate and graduate studies. The company was founded in 1931 and is headquartered in Tampa, FL.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

The University of Tampa, Inc. functions as a college/university that offers undergraduate and graduate studies. The company was founded in 1931 and is headquartered in Tampa, FL.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

The University of Tampa, Inc. functions as a college/university that offers undergraduate and graduate studies. The company was founded in 1931 and is headquartered in Tampa, FL.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

The University of Tampa, Inc. functions as a college/university that offers undergraduate and graduate studies. The company was founded in 1931 and is headquartered in Tampa, FL.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

The University of Tampa, Inc. functions as a college/university that offers undergraduate and graduate studies. The company was founded in 1931 and is headquartered in Tampa, FL.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan Laboratories, Inc. is engaged in developing, licensing, manufacturing, marketing and distributing generic and brand pharmaceutical products. The company manufactures and markets over 140 generic products in approximately 360 product strengths covering over 40 therapeutic categories. The company manufactures products for conditions ranging from angina to arthritis, depression to diabetes, pain to Parkinson's disease and schizophrenia to sleep disorders. The company operates through its three subsidiaries: a) Mylan Pharmaceuticals (Morgantown, West Virginia) is primarily focused on solid oral dose generic pharmaceutical products. b) Mylan Technologies (St. Albans, Vermont) is the pioneer in generic transdermal drug delivery technology and is the producer of generic transdermal patches for the U.S. market. c) UDL Laboratories (Rockford, Illinois) is the number one supplier of unit dose pharmaceuticals to hospitals and other institutions across the United States. The company was incorporated in 1970 and is headquartered in Canonsburg, PA.

Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.